DAZAP1 and gastric cancer: Analysis of the GEO database (GSE14210 and GSE15459 cohorts) indicated that GC patients with elevated DAZAP1 mRNA had worse overall survival (Supplemental Figure 1C, P = 0.006) and progression-free survival (Supplemental Figure 1D, P = 0.007) compared with those with low expression.